시장보고서

상품코드

1630989

경화요법 시장 규모, 점유율, 동향 분석 보고서 : 약제별, 종류별, 용도별, 지역별, 부문별 예측(2025-2030년)

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 12월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

경화요법 시장 성장과 동향:

그랜드 뷰 리서치(Grand View Research, Inc.)의 최신 보고서에 따르면, 세계 경화요법 시장 규모는 2025년부터 2030년까지 연평균 4.4%의 CAGR로 확대되어 2030년에는 15억 달러에 달할 것으로 추정됩니다. 경화요법은 망상정맥류, 하지정맥류, 하지정맥류에 대한 1차 치료로 널리 사용되는 비침습적 시술입니다. 이 시술은 통증, 안면 홍조, 부종, 경련과 같은 관련 증상의 치료를 돕고, 이를 감소시키고 궁극적으로 사라지게 하는 용액(경화제)을 영향을 받은 정맥에 직접 주입하는 것으로 구성됩니다. 적용 부위에 대한 더 나은 노출, 덜 침습적인 기술의 사용, 피부과학의 발전, 정맥류 발생률 및 노인 인구 증가와 같은 요인이 시장 성장을 촉진하고 있습니다.

정맥류 치료에 사용되는 경화제는 세정제, 세척제, 고삼투압제/삼투압제, 화학적 자극제로 분류됩니다. 나트륨 테트라데실 설페이트(Sotradecol)와 폴리도카놀(Asclera), 나트륨 모르핀산염(Scleromate), 에탄올아민 올레산염(Ethamoline)과 같은 약품은 모두 정맥 손상을 치료하고 그 영향을 완화하는 데 사용되는 FDA 승인 경화제입니다. 승인된 경화제입니다. 혈관외과 학회에 따르면, 선진국의 경우 여성의 33.0% 이상, 남성의 약 17.0%가 모세혈관확장증이나 정맥류로 인해 의사의 진료를 받고 있으며, 미국에서만 35.0%의 사람들에게 영향을 미치고 있습니다.

NCBI에 따르면, 전체 성인의 20.0%가 평생 동안 정맥류에 걸릴 수 있으며, 고령화 사회와 여성에서 그 유병률이 더 높으며, 이러한 요인들은 정맥류 시장의 성장을 촉진할 것으로 예상됩니다. 이러한 요인들이 시장 성장을 촉진할 것으로 예상됩니다. 그러나 일부 환자의 경우 색소침착, 탈색, 흉터, 알레르기 반응 등 시술의 부작용이 시장 성장에 걸림돌이 될 수 있습니다.

경화요법 시장 : 분석 개요

세정제 부문은 FDA의 높은 승인, 낮은 혈전 형성 위험, 효능, 의사들 사이에서 인기가 높아 2024년 43.5%의 매출 점유율로 시장을 장악했습니다.
발포 경화요법 부문은 액체 경화요법보다 현장 노출도가 높고 결과가 좋기 때문에 예측 기간 동안 빠르게 성장할 것으로 예상됩니다.
북미 경화요법 시장은 새로운 기술에 대한 수요 증가, 주요 기업의 대규모 풀, 정맥류 유병률 증가, 지역 내 첨단 의료 인프라로 인해 2024년 44.5%의 매출 점유율로 전 세계를 지배했습니다.
아시아태평양의 경화요법 시장은 예측 기간 동안 5.7%의 가장 높은 CAGR을 기록할 것으로 예상됩니다.

시장 점유율 : 지역별(2024년·2030년)
시장 대시보드 : 지역별
시장 규모 예측과 동향 분석(2018-2030년)
북미
- 국가별(2018-2030년)
- 미국
- 캐나다
유럽
- 국가별(2018-2030년)
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 국가별(2018-2030년)
- 브라질
- 멕시코
- 아르헨티나
중동 및 아프리카
- 국가별(2018-2030년)
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

시장 진출 기업 : 개요
기업 시장 포지션 분석
기업 분류
전략 매핑
기업 개요/상장 기업
- LGM Pharma
- Troikaa
- Viatris Inc.
- Omega Pharmaceuticals Pvt. Ltd.
- Merz Pharma
- ENDO-FLEX GmbH.
- Perrigo Company plc
- Medi-Globe GmbH
- Medtronic
- AngioDynamics

KSM 25.02.28

Sclerotherapy Market Growth & Trends:

The global sclerotherapy market size is estimated to reach USD 1.50 billion by 2030, expanding at a CAGR of 4.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights:

The detergents segment dominated the market with a revenue share of 43.5% in 2024 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors
The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy
North America sclerotherapy market dominated the global with a revenue share of 44.5% in 2024 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region
Asia Pacific sclerotherapy market is expected to register the highest CAGR of 5.7% over the forecast period

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Agents
- 1.2.2. Type
- 1.2.3. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Sclerotherapy Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Sclerotherapy Market: Agents Business Analysis

4.1. Agents Market Share, 2024 & 2030
4.2. Agents Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Agents, 2018 to 2030 (USD Billion)
4.4. Detergents
- 4.4.1. Detergents Market, 2018 - 2030 (USD Billion)
4.5. Chemical Irritants
- 4.5.1. Chemical Irritants Market, 2018 - 2030 (USD Billion)
4.6. Osmotic Agents
- 4.6.1. Osmotic Agents Market, 2018 - 2030 (USD Billion)

Chapter 5. Sclerotherapy Market: Type Business Analysis

5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
5.4. Ultrasound Sclerotherapy
- 5.4.1. Ultrasound Sclerotherapy Market, 2018 - 2030 (USD Billion)
5.5. Liquid Sclerotherapy
- 5.5.1. Liquid Sclerotherapy Market, 2018 - 2030 (USD Billion)
5.6. Foam Sclerotherapy
- 5.6.1. Foam Sclerotherapy Market, 2018 - 2030 (USD Billion)

Chapter 6. Sclerotherapy Market: Application Business Analysis

6.1. Application Market Share, 2024 & 2030
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
6.4. Varicose Veins
- 6.4.1. Varicose Veins Market, 2018 - 2030 (USD Billion)
6.5. Malformed Lymph Vessels
- 6.5.1. Malformed Lymph Vessels Market, 2018 - 2030 (USD Billion)
6.6. Hemorrhoids
- 6.6.1. Hemorrhoids Market, 2018 - 2030 (USD Billion)
6.7. Hydroceles
- 6.7.1. Hydroceles Market, 2018 - 2030 (USD Billion)

Chapter 7. Sclerotherapy Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Europe
- 7.5.1. Europe Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.7. Norway
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Competitive Insights
  - 7.5.7.4. Norway Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.8. Denmark
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Competitive Insights
  - 7.5.8.4. Denmark Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.9. Sweden
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Competitive Insights
  - 7.5.9.4. Sweden Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Japan Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. China Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. South Korea Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.6. Australia
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. Australia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Competitive Insights
  - 7.6.7.4. Thailand Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.7. Latin America
- 7.7.1. Latin America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.7.3. Mexico
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Mexico Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.7.4. Argentina
  - 7.7.4.1. Key Country Dynamics
  - 7.7.4.2. Regulatory Framework
  - 7.7.4.3. Competitive Insights
  - 7.7.4.4. Argentina Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.8. MEA
- 7.8.1. MEA Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework
  - 7.8.5.3. Competitive Insights
  - 7.8.5.4. Kuwait Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. LGM Pharma
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Agents Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Troikaa
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Agents Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Viatris Inc.
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Agents Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Omega Pharmaceuticals Pvt. Ltd.
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Agents Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Merz Pharma
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Agents Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. ENDO-FLEX GmbH.
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Agents Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Perrigo Company plc
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Agents Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Medi-Globe GmbH
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Agents Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Medtronic
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Agents Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. AngioDynamics
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Agents Benchmarking
  - 8.5.10.4. Strategic Initiatives

경화요법 시장 규모, 점유율, 동향 분석 보고서 : 약제별, 종류별, 용도별, 지역별, 부문별 예측(2025-2030년)

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030

경화요법 시장 성장과 동향:

경화요법 시장 : 분석 개요

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 경화요법 시장 : 변수, 동향, 범위

제4장 경화요법 시장 : 약제별 비즈니스 분석

제5장 경화요법 시장 : 종류별 비즈니스 분석

제6장 경화요법 시장 : 용도별 비즈니스 분석

제7장 경화요법 시장 : 지역별 추정·동향 분석